Marco Trovò CRO-Aviano

Similar documents
8/16/2011. (Blanco et al. IJROBP 2005) (In press, IJROBP)

CT appearance of radiation injury of the lung after stereotactic body radiation therapy (SBRT) for lung cancers: a pictorial review

Imaging follow-up after stereotactic ablative radiotherapy (SABR) for lung tumors

Radiological changes following stereotactic radiotherapy for stage I lung cancer. M. Dahele, D. Palma, F. Lagerwaard, B. Slotman, S.

The Evolution of SBRT and Hypofractionation in Thoracic Radiation Oncology

Lung Cancer Radiotherapy

ASTRO Andrew J. Hope, M.D.

Dose escalation for NSCLC using conformal RT: 3D and IMRT. Hasan Murshed

NRG Oncology Lung Cancer Portfolio 2016

Imaging of cardio-pulmonary treatment related damage. Radiotheraphy and Lung

Outline. WBRT field. Brain Metastases. Whole Brain RT Prophylactic WBRT Stereotactic radiosurgery (SRS) 1 fraction Stereotactic frame

肺癌放射治療新進展 Recent Advance in Radiation Oncology in Lung Cancer 許峰銘成佳憲國立台灣大學醫學院附設醫院腫瘤醫學部

Thoracic Recurrences. Soft tissue recurrence

4D Radiotherapy in early ca Lung. Prof. Manoj Gupta Dept of Radiotherapy & oncology I.G.Medical College Shimla

An update on NTCP data

Pulmonary changes induced by radiotherapy. HRCT findings

Tecniche Radioterapiche U. Ricardi

Improving the accuracy of radiation pneumonitis dose response models

Update on Limited Small Cell Lung Cancer. Laurie E Gaspar MD, MBA Prof/Chair Radiation Oncology University of Colorado Denver

Stereotactic Body Radiation Therapy and Radiofrequency Ablation 2014 Masters of Minimally Invasive Surgery

Advances in external beam radiotherapy

and Strength of Recommendations

7/30/2018. Review of NTCP models for Thoracic radiotherapy: where are we? Maria Thor, PhD

CPT code semantics 8/18/2011. SBRT Planning Case Studies. Spectrum of applications of SBRT. itreat

Recording Toxicity: the QUANTEC model. Michela Buglione di Monale Nadia Pasinetti Cattedra di Radioterapia

THE ROLE OF RADIATION THERAPY IN MANAGEMENT OF PANCREATIC ADENOCARCINOMA. TIMUR MITIN, MD, PhD

Questions may be submitted anytime during the presentation.

Radiotherapy Planning (Contouring Lung Cancer for Radiotherapy dose prescription) Dr Raj K Shrimali

Overview of Advanced Techniques in Radiation Therapy

Flattening Filter Free beam

Novel techniques for normal tissue toxicity modelling. Laura Cella Institute of Biostructures and Bioimaging National Research Council of Italy

Clinical experience with TomoDirect System Tangential Mode

Hot topics in Radiation Oncology for the Primary Care Providers

Jefferson Digital Commons. Thomas Jefferson University. Maria Werner-Wasik Thomas Jefferson University,

Innovation in radiotherapy: How to prove its value for money?

The relationship between pulmonary function metrics and radiation-induced lung injury

Predictors of Radiotherapy Induced Bone Injury (RIBI) after stereotactic lung radiotherapy

SBRT in early stage NSCLC

PEDIATRIC ORBITAL TUMORS RADIOTHERAPY PLANNING

OBJECTIVES. Solitary Solid Spiculated Nodule. What would you do next? Case Based Discussion: State of the Art Management of Lung Nodules.

Utility of 18 F-FDG PET/CT in metabolic response assessment after CyberKnife radiosurgery for early stage non-small cell lung cancer

Collection of Recorded Radiotherapy Seminars

Comparison of IMRT and VMAT Plan for Advanced Stage Non-Small Cell Lung Cancer Treatment

Sarcoma and Radiation Therapy. Gabrielle M Kane MB BCh EdD FRCPC Muir Professorship in Radiation Oncology University of Washington

In-Young JO 1, Chul-Seung KAY 1, *, Ji-Yoon KIM 1, Seok-Hyun SON 1, Yong-Nam KANG 1, Ji-Young JUNG 1 and Ki-Jun KIM 2 INTRODUCTION

Stereotactic Body Radiotherapy (SBRT) For HCC T A R E K S H O U M A N P R O F. R A D I A T I O N O N C O L O G Y N C I, C A I R O U N I V.

Stereotactic radiotherapy

Stereotactic MR-guided adaptive radiotherapy for central lung tumors. Professor Suresh Senan, VU University Medical Center

The Role of Radiation Therapy in the Treatment of Brain Metastases. Matthew Cavey, M.D.

Therapeutic ratio - An Overview. Past Present Future Prof Ramesh S Bilimaga

DOES RADIOTHERAPY TECHNIQUE / DOSE / FRACTIONATION REALLY MATTER? YES

An Update on Radiation Therapy for Prostate Cancer

Palliative radiotherapy near the end of life for brain metastases from lung cancer: a populationbased

IMRT - the physician s eye-view. Cinzia Iotti Department of Radiation Oncology S.Maria Nuova Hospital Reggio Emilia

Focus on treatment complications and optimal management: radiation oncology

SBRT TREATMENT PLANNING: TIPS + TRICKS. Rachel A. Hackett CMD, RT(T)

Role of Belly Board Device in the Age of Intensity Modulated Radiotherapy for Pelvic Irradiation

Potential conflicts-of-interest. Respiratory Gated and Four-Dimensional Tumor Tracking Radiotherapy. Educational objectives. Overview.

The Physics of Oesophageal Cancer Radiotherapy

Imaging of Scattered Radiation for Real Time Tracking of Tumor Motion During Lung SBRT

MRI Applications in Radiation Oncology:

STAGE I INOPERABLE NSCLC RADIOFREQUENCY ABLATION OR STEREOTACTIC BODY RADIOTHERAPY?

8/3/2016. Background. CT-Ventilation. Validation, Clinical Endpoints and Opportunities for CT Ventilation. 4DCT-Ventilation Imaging.

RTOG Lung Cancer Committee 2012 Clinical Trial Update. Wally Curran RTOG Group Chairman

Radiobiological Considerations

Translational Radiation Oncology, Physics & Supportive Care (TROP) Mark De Ridder, Wim Distelmans & Dirk Verellen

Conflicts of Interest

SABR. Outline. Stereotactic Radiosurgery. Stereotactic Radiosurgery. Stereotactic Ablative Radiotherapy

Credentialing for the Use of IGRT in Clinical Trials

The role of Radiation Oncologist: Hi-tech treatments for liver metastases

Stereotactic Body Radiotherapy for Lung Lesions using the CyberKnife of-the-art and New Innovations

Partial Breast Irradiation using adaptive MRgRT

RESEARCH ARTICLE. Evaluation of the Radiation Pneumonia Development Risk in Lung Cancer Cases

Demands and Perspectives of Hadron Therapy

Prediction of toxicity in concurrent chemoradiation for non-small cell lung cancer Uijterlinde, W.I.

56 th Annual Meeting American Society for Radiation Oncology. Advances in Lung Caner News Briefing

Regional Variation of Interfraction Tumor Breathing Motion in Lung Stereotactic Body Radiation Therapy (SBRT)

Clinical Implications Of Dose Summation And Adaptation

NORMAL TISSUE COMPLICATION PROBABILITY MODELLING OF FATAL ACUTE LUNG TOXICITY AFTER EXTERNAL RADIOTHERAPY TREATMENT OF LUNG TUMOURS

IMRT RTOG Definitive IMRT for Low Risk Prostate Cancer. All about dose and dose matters, probably Although hormones may matter

Reirradiazione. La radioterapia stereotassica ablativa: torace. Pierluigi Bonomo Firenze

A Population-Based Study on the Uptake and Utilization of Stereotactic Radiosurgery (SRS) for Brain Metastasis in Nova Scotia

Stereotactic radiotherapy (SBRT) as a sole or salvage therapy in non-small cell lung cancer patients

TREATMENT TIME & TOBACCO: TWIN TERRORS Of H&N Therapy

Aytul OZGEN 1, *, Mutlu HAYRAN 2 and Fatih KAHRAMAN 3 INTRODUCTION

Clinical Protontherapy Head and Neck cancer

Clinical Aspects of SBRT in Abdominal Regions Brian D. Kavanagh, MD, MPH University of Colorado Department of Radiation Oncology

Pitfalls in SBRT Treatment Planning for a Moving Target

Where are we with radiotherapy for biliary tract cancers?

Stereotactic ablative radiotherapy in early NSCLC and metastases

Dosimetric Analysis of 3DCRT or IMRT with Vaginal-cuff Brachytherapy (VCB) for Gynaecological Cancer

Pancreatic Cancer and Radiation Therapy

Future Directions in Prostate Cancer: The Case for Protons. John J. Coen, MD Helen & Harry Gray Cancer Center

Stereotactic MR-guided adaptive radiation therapy (SMART) for locally advanced pancreatic tumors

8/2/2018. Acknowlegements: TCP SPINE. Disclosures

CALGB Thoracic Radiotherapy for Limited Stage Small Cell Lung Cancer

Disclosure. Paul Medin teaches radiosurgery courses sponsored by BrainLAB Many animals (and humans) were harmed to make this presentation possible!

Acute and Chronic Lung Disease

Silvia Pella, PhD, DABR Brian Doozan, MS South Florida Radiation Oncology Florida Atlantic University Advanced Radiation Physics Boca Raton, Florida

New Thinking on Fractionation in Radiotherapy

Transcription:

From pre-clinical research to clinical practice in radiation therapy: new predictive factors and biological markers to predict normal tissue toxicity after radiation therapy of the lung. Marco Trovò CRO-Aviano Reggio Emilia 16 Aprile 2010

Outline Introduction Traditional predictive factors of lung toxicity Non-traditional predictive factors of lung toxicity Biological markers as predictors of radiation toxicity Trial proposal

Outline Introduction Traditional predictive factors of lung toxicity Non-traditional predictive factors of lung toxicity Biological markers as predictors of radiation toxicity Trial proposal

Let s start from the beginning: radiobiology The tolerance of normal tissues to radiation limits the dose that can be safely delivered in the treatment of malignancies. For many years, the only option available was to limit the dose and volume of irradiated tissue. Theoretical curves showing the probability of tumor control and normal tissue complications. Both curves have a threshold and are log sigmoid in nature. The art of radiotherapy is to increase the distance between these two curves; that is, to derive a therapeutic benefit. If the normal tissue damage curve is to the left of that for TCP, tumor control is unlikely without unacceptable normal tissue complications.

Importance of identification of predictive factors able to select patients at increased or decreased risk of treatment-related injury.

Importance of identification of predictive factors able to select patients at increased or decreased risk of treatment-related injury. SBRT 0-3 months 3-6 months 6-18 months 24 months Baseline 3 months after SBRT 5 months after SBRT 9 months after SBRT 25 months after SBRT M, 75 y/o, NSCLC Patchy GGO Diffuse consolidation Dense consolidation and bronchiectasis Dense consolidation and bronchiectasis

Importance of identification of predictive factors able to select patients at increased or decreased risk of treatment-related injury. SBRT 0-3 months 3-6 months 6-18 months 24 months Baseline 1 month after SBRT 5 months after SBRT 12 months after SBRT 24 months after SBRT F, 51 y/o, NSCLC No radiologic injury No radiologic injury Scar-like fibrosis Scar-like fibrosis

Outline Introduction Traditional predictive factors of lung toxicity Non-traditional predictive factors of lung toxicity Biological markers as predictors of radiation toxicity Trial proposal

Traditional predictive factors of lung toxicity Age Patient specific Gender Smoking Comorbidities PS Treatment specific Dose Dose per fraction Fractionations Dosimetric Parameters

Traditional predictive factors of lung toxicity Dosimetric parameters V20 V30 MLD lung volume that receive a dose > 20 Gy NTCP models

Traditional predictive factors of lung toxicity V20 Pneumonitis GRADE 2 V20 <22% 22-31% 32-40% >40% Rischio 0 7% 13% 36% Graham IJROBP 1999

Traditional predictive factors of lung toxicity

Outline Introduction Traditional predictive factors of lung toxicity Non-traditional predictive factors of lung toxicity Biological markers as predictors of radiation toxicity Trial proposal

Superior/Inferior Position Non-Traditional predictive factors of lung toxicity Tumor location associated with risk of 1 0.8 0.6 0.4 0.2 Right Lung: 47/137 (34.3%) pneumonitis Left Lung: 22/91 (24.2%) Superior 25%: 15.9% (7/44) Middle 25%: 30.2% (42/139) Inferior 50%: 44.4% (20/45) 0 0 0.2 0.4 0.6 0.8 1 Right/Left Position Bradley, IJROBP 2007

Non-Traditional predictive factors of lung toxicity Univariate Correlations Predicting Radiation Pneumonitis Parameter WU (Spearman s) MLD 0.18 V 20 V 13 0.18 D 35 0.18 0.19 D 15 0.11 GTV-SI GTV-AP 0.23 0.02 Bradley, IJROBP 2007

Non-Traditional predictive factors of lung toxicity WU/RTOG 9311: Pneumonitis Data Multi-metric Modeling [MLD, COM-SI] [V65, COM-SI] [D25, MLD] Models [MLD, PreTxChemo] [D35, V70] [D35, COM-AP] [ V25, V75] [MLD, COM-LAT] 0 20 40 60 Percentage frequency

Non-Traditional predictive factors of lung toxicity Nomogram on pneumonitis probability Bradley, IJROBP 2007

Non-Traditional predictive factors of lung toxicity High-dose Heart Irradiation is a Statistically Significant Risk Factor for Radiation Pneumonitis J. O. Deasy 1, M. Trovo 2, E. X. Huang 1, Y. Mu 1, I. El Naqa 1, and J. D. Bradley 1 1 Dept. of Radiation Oncology, Washington University School of Medicine, St. Louis, MO 2 University of Milan, Milan, Italy

Non-Traditional predictive factors of lung toxicity Heart volumes of WUSTL archived plans were recontoured within CERR by a single physician (n = 209, with 48 RP events). Heart and normal lung (lung minus gross tumor volume) dose-volume parameters were extracted for further modeling using CERR. Evaluated factors included: clinical (age, gender, race, performance status, weight loss, smoking, histology) dosimetric parameters for heart and normal lungs (D5-D100, V10-V80, mean dose, maximum dose, and minimum dose) treatment factors (chemotherapy, treatment time, fraction size) location parameters (heart center-of-dose, sup-inf within the heart; and center-of-target mass within the normal lungs.) Deasy, ASTRO 2008

Non-Traditional predictive factors of lung toxicity Highest univariate correlations Variable Spearman Corr. Significance D5_Heart 0.256 <0.0002 D10_Heart 0.24 <0.0003 V70_heart 0.239 <0.0003 geud_heart (a=10) Maximum Heart Dose Superior-Inferior position of GTV 0.249 0.227 0.219 <0.0001 <0.0006 <0.0008 Deasy, ASTRO 2008

Non-Traditional predictive factors of lung toxicity Comparison between multivariate model prediction and risk group Comparison of predicted risk of RP by four parameter model (in order of selection: D10_heart, D30_heart, Mean lung dose, DCOMSI_heart) and actual incidence in the population. The patients are binned according to predicted risk of RP by the model (equal patients in each bin). Deasy, ASTRO 2008

Non-Traditional predictive factors of lung toxicity D10=58Gy D10: hottest spot at 10% of organ volume

Non-Traditional predictive factors of lung toxicity Scatter Plot between D10_Heart and GTV_COMSI Note increasing risk with high-dose heart irradiation that dominates previously reported lung location effect (Hope, IJROBP 2006). Deasy, ASTRO 2008

Dosimetric parameters (V20, MLD, NTCP) and tumor-related factors allowed for patient-stratified dose escalation both for locally-advanced and for early-stage NSLCL leading to a major improvement of the outcome!

In Locally-Advanced NSCLC, by a dosimetricparameter patient stratification (V20)

Graham Retrospective studies Claude Prospective validations DOSE-ESCALATION RTOG 93-11 RTOG 01-17 RT 77-83 Gy CRT 74 Gy RANDOMIZED TRIAL!!! RTOG 06-17 60 Gy VS 74 Gy

In early-stage NSCLC, by the introduction of dose-perfraction escalation (Stereotactic-Body Radiation Therapy) ASTRO meeting 2008 100 Local failure 1.0 90 0.8 80 70 Control rate 0.6 0.4 0.2 Overall local control rate Survival rate rate(%) 60 50 40 30 Local control by maximum dose p=0.07 20 0.0 0 10 20 Time (Months) 30 40 50 10 Maxdose>=67 Gy (n=27) MaxDose < 67 Gy (n=62) 0 0 5 10 15 20 25 30 35 Time (Years)

Author N of patients Pneumonitis Uematsu 66 Grade 3 0% Nagakawa 22 Grade 3 0% Onishi 257 Grade 2 5.4% Wulf 61 Grade 3 3% Hara 23 Grade 3 4% Lagerwaard 206 Grade 3 3% Timmerman 37 Grade 3 5.4% Bradley 67 Grade 2 3%

Lung Cancer 2009 Radiot.Oncol. 2007 IJROBP 2006

Early changes: pneumonitis Before 6 months from SBRT 1. Diffuse consolidation 2. Diffuse ground-glass opacity (GGO) 3. Patchy consolidation and GGO 4. Patchy GGO 5. No changes

SBRT Early changes M, 85 y/o, NSCLC; baseline 1.DIFFUSE CONSOLIDATION Diffuse and homogeneous increase in parenchymal attenuation, obscuring vessels and bronchi 4 months after SBRT Air bronchogram

SBRT Early changes M, 80 y/o, NSCLC; 5 months after SBRT 2. DIFFUSE GGO Hazy increase of parenchymal attenuation... L M, 93 y/o, H&N met; 5 months after SBRT

SBRT Early changes F, 78 y/o, NSCLC; 6 months after SBRT 3. PATCHY CONSOLIDATION AND GGO Areas of hazy and dense increased parenchymal attenuation interspersed in normal lung.. Baseline L F, 66 y/o, NSCLC 5 months after SBRT

SBRT Early changes F, 75 y/o, NSCLC; 4 months after SBRT 4. PATCHY GGO L Areas of hazy increased parenchymal attenuation interspersed in normal lung L = lesion.. M, 60 y/o, NSCLC; 3 months after SBRT

SBRT Early changes M, 78 y/o, NSCLC; baseline 5. No change 4 months after SBRT..

Late changes: fibrosis (after 6 months after SBRT) 1. Modified conventional pattern 2. Mass-like pattern 3. Scar-like pattern 4. No change

SBRT Late changes M, 75 y/o, NSCLC; 7 months after SBRT 1.MODIFIED CONVENTIONAL PATTERN Parenchymal consolidation, volume loss, bronchiectasis M, 75 y/o, NSCLC; 9 months after SBRT..

SBRT Late changes 2. MASS-LIKE PATTERN DIFFICULT DDx WITH RECURRENCE!!! Focal area of increased density F, 52 y/o, NSCLC; 11 months after SBRT

SBRT Late changes M, 80 y/o, NSCLC; 10 months after SBRT 3. SCAR-LIKE PATTERN Linear opacity and volume loss

SBRT Late changes F, 63 y/o, NSCLC; baseline 4. No change 11 months after SBRT 22 months after SBRT

Lung Cancer 2009 1. No correlation between lung injuries and tumor dimension or radiation dose 2. No correlation between lung injuries and age, smoking habits, comorbidities, PS, or emphysema 3. Steroids administration did not impact on the development of late fibrosis, but seems to delay early pneumonitis

Outline Introduction Traditional predictive factors of lung toxicity Non-traditional predictive factors of lung toxicity Biological markers as predictors of radiation toxicity Trial proposal

2. There are no dosimetric models to predict radiation lung injury after SBRT! Baseline 3 months after SBRT 5 months after SBRT 9 months after SBRT 25 months after SBRT

1. The accuracy of prediction of lung tissue toxicity derived from solely dosimetric models is insufficient! Besides dosimetric factors, biological parameters might be considered. Many studies looked at correlations between risk of radiation lung injury and variation in profibrogenic and pro-inflammatory cytokines.

Initial tissue damage from RT is generated by the direct action of reactive oxygen species (ROS) on DNA Simplified model of the complex network of interacting processes and signals in the pathogenesis of radiation lung injury

Within this cascade, there are dominant cytokines and growth factors, which are up-regulated and peak at different time points. Studies were conducted to investigate the feasibility of these biological markers as predictors of radiation-induced lung injury.

Clinical studies measuring TGF-B in patients undergoing RT, to predict radiation pneumonitis or fibrosis

Clinical studies measuring other than TGF-B in patients undergoing RT

Biological markers predicting patients at risk of lung injury are awaited: Allow for patient-stratified dose escalation maximizing individual therapeutic gain Early diagnosis of early radiation pneumonitis Diagnostic tool to distinguish radiation pneumonitis from differential diagnosis

Outline Introduction Traditional predictive factors of lung toxicity Non-traditional predictive factors of lung toxicity Biological markers as predictors of radiation toxicity Trial proposal

Trial proposal at CRO-Aviano Objectives: To describe early and late lung radiographic injuries following helical-imrt To correlate such injuries to patient and treatment characteristics To implement a NTCP model to estimate the risk of early and late lung injuries To identify biological markers predicting the risk of radiation injuries To identify genetic markers (gene polymorphism) predicting normal tissue toxicity and tumor control

Trial proposal at CRO-Aviano To identify biological markers predicting the risk of radiation injuries: Multiplex assays to facilitate the simultaneous evaluation of multiple proteins: to generate a sophisticated normal tissue injury risk profile for an individual patient! Flexible analyzer based on the principles of flow cytometry enables you to multiplex (simultaneously measure) up to 100 analytes in a single microplate well, using very small sample volumes.

Thank you for your attention marco.trovo@cro.it